A ngiogenesis (capillary growth), lymphangiogenesis (lymphatic vessel growth), arteriogenesis (enlargement of arteries), and vasculogenesis (in situ formation of blood vessels from vascular stem cells) are crucial for normal embryonic development, growth, and tissue repair. Further understanding of these processes may also contribute to the treatment of many disorders, such as cancer, tissue ischemia, and lymphedema. Vascular endothelial growth factors (VEGFs) are involved in all types of vascular growth. [1] [2] [3] [4] [5] [6] Currently, the human VEGF family consists of 5 members: VEGF-A, -B, -C, -D, and placenta growth factor (PlGF), [7] [8] [9] [10] [11] [12] [13] which differ in their ability to bind to VEGF receptors that are primarily expressed in endothelial cells (ECs): VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4), and neuropilin-1. VEGF-A binds to VEGFR-1 and VEGFR-2 as well as to neuropilin-1, whereas PlGF and VEGF-B bind only to VEGFR-1 and neuropilin-1. 1, 14, 15 VEGF-C and VEGF-D are synthesized and secreted as large precursor forms that are proteolytically processed into mature forms comprising the central VEGF homology domain. 16, 17 Unprocessed forms preferentially signal through VEGFR-3, whereas only the mature forms efficiently trigger VEGFR-2 signaling. 16, 17 Both VEGF-C and -D have been suggested to be mainly lymphangiogenesis factors; their angiogenic potential has been reported to be considerably weaker than that of VEGF-A. 6, 13, 16 In addition to the naturally occurring forms, Joukov et al 18 have generated a mutant factor (VEGF-C 156S ) that binds to VEGFR-3 but not to VEGFR-2.
VEGF receptors have distinct biological roles. VEGFR-2 is considered to mediate most of the angiogenic, survival, and vascular permeability effects of VEGFs and effects on endothelial progenitor cells (EPCs), 1, 3, 19 whereas the role of VEGFR-1 is controversial. Most studies indicate that VEGFR-1 is mainly a decoy receptor existing also as a soluble form, and that it may downregulate VEGFR-2-mediated mitogenesis. 1,19 -21 However, others have reported that the VEGFR-1 ligand PlGF mobilizes EPCs, hematopoietic, and inflammatory cells, and that it may amplify VEGFR-2-mediated effects. 22 There is extensive evidence that VEGFR-3-mediated signaling alone is sufficient for the growth and maintenance of lymphatic vasculature. 2, 23, 24 Nitric oxide (NO) is crucial in VEGF-A-mediated angiogenesis and vascular permeability, 25 but it is not known whether NO is necessary for lymphangiogenesis.
For optimal gene therapy, it is essential to determine which VEGF family member is most suitable for angiogenesis/ lymphangiogenesis in a given tissue. To address this issue, we compared adenoviruses encoding human VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-C 156S in rabbit hindlimb skeletal muscle. The objective was to study the direct effects of these VEGFs on local blood and lymphatic vessel growth, blood perfusion, and vascular permeability in the injected muscles and thus establish a basis for the selection of most suitable growth factors for each purpose. In addition, the significance of proteolytic processing of VEGF-D in vivo was studied by using adenoviruses expressing both its full-length and mature (⌬N⌬C) forms. We further explored the effects of these growth factors on vascular smooth muscle cells (SMCs) and pericytes, and evaluated the role of NO in vascular permeability, angiogenesis, and lymphangiogenesis induced by VEGF-D in vivo.
Materials and Methods
The superficial femoral artery of New Zealand White rabbits (nϭ66) was excised and two reentry arteries for collaterals near the knee joint were ligated in order to induce collateral artery growth in the hindlimb as described. 4 The nonischemic thigh region lacking confounding endogenous upregulation of VEGF-A and VEGFR-2 26 was used for the analysis of the effects induced by VEGFs. Seven days after surgery, animals received intramuscular (IM) injections of human clinical grade adenoviruses (total dose 10 11 viral particles [vp]) encoding human VEGF-A 165 , 8 VEGF-B 167 , 10 full-length VEGF-C, 11 full-length or mature (⌬N⌬C) VEGF-D, 13 or VEGF-C 156S18 (nϭ3 to 8 in each group). N-Nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) 27 was used to study whether angiogenesis, lymphangiogenesis, and vascular permeability promoted either by the full-length or mature form of VEGF-D are dependent on NO production. Transduced hindlimbs were monitored for vascular permeability and subsequent edema with gadodiamide (GdDTPA-BMA)-contrast agent-enhanced T 2 *-weighted MRI (MRI) 4,26 5 days after gene transfer (GT). Muscle perfusion and vascular permeability were assessed quantitatively with fluorescent microspheres and a modified Miles assay, respectively, 6 days after GT. 4 Thereafter, muscle samples were collected for histological analyses. 4, 26 All animal experiments were approved by the Experimental Animal Committee, University of Kuopio.
For further details, see the expanded Materials and Methods in the online data supplement available at http://www.circresaha.org.
Results

VEGFR-2 Ligands VEGF-A and VEGF-D
⌬N⌬C
Induce the Strongest Angiogenesis Effects in Skeletal Muscle
Effects of VEGFs were evaluated in nonischemic muscles in areas outside the needle track in order to exclude the confounding effects of endogenous growth factors induced by injection trauma or ischemia. Control virus (10 11 vp/mL) encoding the LacZ marker gene did not induce angiogenesis or significant inflammation in rabbit skeletal muscle ( Figures  1a and 1c) , whereas an angiogenesis response characterized by a remarkable microvessel enlargement was induced by both AdVEGF-A and AdVEGF-D ⌬N⌬C (Figures 1b, 1d , and 1i). In AdVEGF-D ⌬N⌬C transduced muscles, the size of enlarged vessels sometimes exceeded that of surrounding skeletal myocytes. Adenoviruses encoding full-length VEGF-C and VEGF-D also enlarged the microvessels, although less than AdVEGF-A and AdVEGF-D ⌬N⌬C (Figures 1f  and 1h ), whereas AdVEGF-B and AdVEGF-C 156S had no effects on blood vessels (Figures 1e and 1g ). VEGFR-2 and ␣ v ␤ 3 integrin were not detectable with immunostaining in capillaries of intact and AdLacZ transduced muscles (data not shown). In contrast, both VEGF-A (data not shown) and VEGF-D ⌬N⌬C upregulated VEGFR-2 and ␣ v ␤ 3 integrin expression in the ECs (Figures 1j and 1k) .
Interestingly, there were differences in the angiogenesis patterns promoted by AdVEGF-A and AdVEGF-D
⌬N⌬C
. The strongest effects after AdVEGF-A treatment occurred in connective tissue between muscle bundles and in muscle fascias, whereas angiogenesis stimulated by AdVEGF-D ⌬N⌬C was more diffuse (Figures 2b, 2c, 2f, and 2g) . Furthermore, AdVEGF-A generated more glomeruloid bodies (clusters of tortuous vessels 28 ) than AdVEGF-D ⌬N⌬C (Figure 2b ). 
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VEGFR-3 Ligands VEGF-C, VEGF-C 156S , and VEGF-D Promote Lymphangiogenesis
Histochemical staining of lymphatic endothelial cells for 5Ј nucleosidase activity 29 and an intraarterial injection of Ricinus Communis lectin (data not shown) revealed that the CD31-positive but ␣-SMA-negative vessels in the interstitial connective tissue between the muscle bundles were lymphatics, not blood vessels (Figures 2d through 2j) .
Adenovirus encoding the full-length VEGF-D induced the strongest lymphatic vessel growth as almost all the interstitial connective tissue in transduced muscles was filled with lymphatic vasculature 6 days after GT (Figures 2d and 2h ). AdVEGF-D
⌬N⌬C
, AdVEGF-C, and AdVEGF-C 156S were also potent lymphangiogenesis inducers (Figures 2g, 2i , and 2j). Remarkably, the adenovirus encoding the VEGFR-3 selective mutant VEGF-C 156S stimulated exclusively lymphangiogenesis, whereas AdVEGF-A (Figures 2f and 2j ) and AdVEGF-B (data not shown) had no effects on lymphatic vessels.
VEGF-A and VEGF-D ⌬N⌬C Induce Arteriogenesis
In AdLacZ muscles, only a portion of the capillaries had ␣-SMA-positive pericytes and there were few proliferating SMCs (Figures 2k and 2o ). In contrast, both in AdVEGF-Aand AdVEGF-D ( Figure 2n ). In these muscles, collateral arteries showed active remodeling with abundant numbers of proliferating SMCs (Figure 2p ), especially in regions of plasma protein extravasation (see following sections).
AdVEGF-A and AdVEGF-D ⌬N⌬C Increase Vascular Permeability and Cause Edema
Extensive vascular permeability and subsequent edema were observed in AdVEGF-A and AdVEGF-D ⌬N⌬C transduced muscles 5 days after GT by contrast agent-enhanced MRI (Figures 3b and 3g) . Extravasated contrast agent was detected under the skin, in the semimembranosus muscle and in its fascias, and in the fat tissue between the medial and lateral muscle compartments. In contrast, AdLacZ or other AdVEGFs did not induce significant vascular permeability effects (Figures 3a, 3c through 3f, 4a, 4c, and 4e) . The modified Miles assay demonstrated strong and quite diffuse vascular permeability in AdVEGF-D ⌬N⌬C transduced muscles (Figure 4b ). Microscopically, extravasated plasma proteins were retained, especially in connective tissue between muscle bundles, around large blood vessels, as well as within muscle fibers surrounded by enlarged, leaky microvessels ( Figures  4d and 4f ).
Angiogenesis and Lymphangiogenesis Profiles of Adenovirally Delivered VEGFs
A quantitative comparison of capillary density and mean area, total capillary area, plasma protein extravasation, regional muscle perfusion, and total lymphatic vessel area in the transduced muscles 6 days after GT gave an angiogenesis or lymphangiogenesis profile for each VEGF. Surprisingly, only AdVEGF-A GT significantly increased the capillary density (Figure 5a ). In contrast, AdVEGF-D ⌬N⌬C enlarged the mean capillary area as much as 14-fold as compared with AdLacZ control without inducing any increase in the capillary number (Figures 5a and 5b) . The corresponding increase in the mean capillary size was 6.4-fold with AdVEGF-A. Effects on microvessel enlargement reached a statistical significance also with AdVEGF-C and AdVEGF-D with 2.5-and 2.2-fold increases, respectively (Figure 5b) .
AdVEGF-D ⌬N⌬C and AdVEGF-A GT resulted in dramatic 24-and 13-fold increases, respectively, in plasma protein extravasation as measured by the modified Miles assay (Figure 5b ). Although AdVEGF-C and AdVEGF-D had weak effects on capillary enlargement, they did not significantly enhance plasma protein extravasation.
About 6% and 8% of the AdVEGF-A-and AdVEGF-D ⌬N⌬C -transduced muscles were covered by microvessel lumens, respectively (Figure 5c ). These figures were much greater than in AdVEGF-C-(1.8%), AdVEGF-D-(1.7%), and AdLacZ-treated muscles (0.7%). Regional perfusion was increased accordingly in the transduced muscles. AdVEGF-A, AdVEGF-D
⌬N⌬C
, and AdVEGF-C induced statistically significant 4.0-, 3.2-, and 2.0-fold increases in perfusion, respectively ( Figure 5c ). As shown in Figure 5d , lymphatic vessel area of muscles (%) was strongly increased with adenoviruses expressing the VEGFR-3 ligands VEGF-C (1.5%), VEGF-C 156S (1.3%), VEGF-D (2.6%), and VEGF-D ⌬N⌬C (1.4%) as compared with AdLacZ (0.12%).
Finally, angiogenesis and lymphangiogenesis indices were calculated for each VEGF. These indices illustrate the balance between blood and lymphatic vessel growth ( Figure 6 ). VEGF-A was the only to induce angiogenesis but not lymphangiogenesis, whereas full-length VEGF-C and VEGF-D were found to be mainly, and VEGF-C 156S exclusively, lymphangiogenic. The mature form VEGF-D ⌬N⌬C induced significant growth of both vessel types. VEGF-B was inefficient both for angiogenesis and lymphangiogenesis. 
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NO synthase inhibitor L-NAME significantly blocked capillary enlargement and increases in vascular permeability after AdVEGF-D ⌬N⌬C treatment as shown in Figures 3h and 7a . In contrast, NO synthase inhibition did not affect lymphangiogenesis induced by full-length VEGF-D (Figure 7b ).
Vascular Permeability Correlates With Microvessel Size
A positive correlation was found when the mean microvessel area calculated from each transduced muscle was plotted against the respective vascular permeability ratio (Figure 7c) . A positive correlation also existed between the total capillary area and the regional muscle perfusion, indicating that the anatomical observation about capillary vessel growth is in line with a physiological measure of blood flow (Figure 7d) . However, the correlation was best with physiological (small) capillary sizes because microspheres (diameter 15 m) do not likely get stuck in strongly enlarged capillaries (diameter Ͼ15 m), which may underestimate perfusion values obtained with this method.
Discussion
We analyzed the human VEGF family members VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-D
⌬N⌬C
, and a VEGFR-3-specific mutant VEGF-C 156S for their effects on angiogen- induced not only EC, but also pericyte and SMC proliferation, and 3-to 4-fold increases in muscle perfusion at rest. A positive correlation was observed between capillary size and vascular permeability. Adenoviruses expressing the fulllength VEGF-C and VEGF-D induced mainly, and the VEGFR-3-specific mutant VEGF-C 156S exclusively, lymphangiogenesis. AdVEGF-D generated the most powerful lymphatic vessel growth, which, unlike angiogenesis, was not affected by NO synthase inhibition. Finally, we found that the VEGFR-1 ligand VEGF-B was ineffective both for angiogenesis and lymphangiogenesis.
We performed GT of different VEGFs in the nonischemic thigh muscles in this rabbit model of collateral artery growth 4 because necrosis, inflammation, and expression of endogenous growth factors caused by ischemia 26 may mask differences between transduced growth factors and make this kind of comparison impossible. Furthermore, therapies designed for augmentation of arteriogenesis should also be effective in nonischemic muscles upstream to ischemia, which is usually the site of collateral growth.
Whereas this in vivo study supports the role for VEGFR-2 signaling as the major regulator of angiogenesis and vascular permeability, our data suggest that VEGFR-1 signaling alone may not be capable of initiating angiogenesis because its ligand VEGF-B was ineffective. Nevertheless, distinct histological characteristics were associated with AdVEGF-Ainduced angiogenesis in comparison with that obtained with AdVEGF-D
. AdVEGF-A increased capillary density and induced the formation of glomeruloid bodies 28 more frequently than AdVEGF-D ⌬N⌬C , which exerted more diffuse effects and strongly enlarged the preexisting microvessels. These findings may relate to the fact that VEGF-A binds to VEGFR-1 and VEGFR-2, 1 whereas VEGF-D ⌬N⌬C binds to VEGFR-2 and VEGFR-3. 13, 17 However, it is more likely that the different affinities of VEGF-A and VEGF-D ⌬N⌬C for the extracellular matrix are responsible for these biological differences. In contrast to VEGF-A 165 , there is no heparanbinding domain in the sequence of VEGF-D
. 1, 13 Furthermore, the selective VEGFR-1 and VEGFR-3 ligands, VEGF-B and VEGF-C 156S , respectively, appeared inert toward blood vessels. Nevertheless, the possibility of subtle interspecies differences on receptor activation, which could modify the biological outcomes, cannot be excluded because human VEGFs were tested in the rabbit. However, according to our previous studies and this work, human and mouse VEGF-A and human VEGF-C have all shown expected potency in rabbits. 4, 30 Further studies are needed to clarify the role of VEGFR-1 in angiogenesis because PlGF, another VEGFR-1 ligand, is angiogenic at least in some circumstances. 22 As expected from in vitro receptor binding profiles 11, 13, 17, 23 and recent in vivo work, 2 we found that VEGFs activating VEGFR-3 induced lymphangiogenesis in rabbit skeletal muscle. The counting of lymphatic vessels was done from CD31 and ␣-SMA double-immunostained sections because of the possibility that molecular markers used for the detection of lymphatic endothelium, such as VEGFR-3 and LYVE-1, may also be expressed on activated ECs of blood vessels or may not be expressed in all lymphatic ECs. 6, 23, 31, 32 VEGF-C stimulated predominantly, and the VEGFR-3-specific mutant VEGF-C 156S exclusively, lymphatic vessel growth. However, lymphangiogenesis induced by the full-length VEGF-D was strongest as nearly all the space between muscle bundles was filled with lymphatics in AdVEGF-D-treated muscles. The ability of the processed form VEGF-D ⌬N⌬C to induce substantially more angiogenesis and less lymphangiogenesis than the full-length form can be explained by the fact that proteolytic processing increases its affinity toward VEGFR-2 more (290-fold) than toward VEGFR-3 (40-fold). 17 Our data also suggest that, at least in nonischemic skeletal muscle, VEGF-D is not efficiently cleaved by proteases. Taken together, our results implicate that VEGF-C, VEGF-D, and VEGF-C 156S could be applicable in the treatment of lymphatic disorders such as primary and secondary lymphedema. 24 Blood vessels formed in response to VEGF-A have been suggested to lack pericytes, 33 and it has been proposed that because of this defect they are prone to regression when VEGF-A levels are decreased. 34 However, our data demonstrate that the expanded vessels induced both by AdVEGF-A and AdVEGF-D ⌬N⌬C are accompanied by an ␣-SMA-positive pericyte coverage, which, together with the large size (diameter up to 50 m), suggests a shift from the midcapillary phenotype toward arterioles, venules, or possibly arteriovenous shunts. Nevertheless, in spite of the efficient pericyte recruitment, our recent study shows that at least in nonischemic skeletal muscle, where excess blood perfusion is not necessary, the enlarged capillaries induced by AdVEGF-A or AdFGF-4 regress after the termination of gene expression. 4 To the best of our knowledge, it has not been shown that VEGFs could induce SMC or pericyte proliferation in vivo and thus these actions are likely indirect. Arterial SMCs and pericyte proliferation occurred in areas of increased plasma protein extravasation, which suggests that protein efflux from the vasculature to the extravascular space may contribute to these processes. 4 For example, extravasation of plasma proteins triggers the clotting cascade, leading to deposition of fibrin gel in the interstitial space. In addition to causing edema, the hydrated fibrin gel is proangiogenic because it provides matrix for cell migration and growth. 35 Additional growth factors that are mitogenic for SMCs, such as PDGFs, may also be upregulated. Furthermore, increased shear stress in the enlarged microvessels and enhanced integrin signaling 36 may further contribute to the transformation of capillaries toward bigger vessels.
The NO synthase inhibitor L-NAME 27 significantly blocked AdVEGF-D ⌬N⌬C -induced vascular effects including capillary enlargement and extravasation of plasma proteins, indicating that, like in the case of VEGF-A, 19, 25 NO is crucial for blood vascular effects stimulated by VEGF-D
. Furthermore, VEGFR-2 and ␣ v ␤ 3 integrin were upregulated on ECs by VEGF-D ⌬N⌬C , suggesting that its angiogenic signaling mechanisms are similar to those of VEGF-A. 1 Furthermore, efficient angiogenesis and VEGFR-2 upregulation by its ligands in nonischemic skeletal muscle shows that ischemia is not requisite for blood vessel growth. In contrast to angiogenesis, inhibition of NOS did not affect lymphangiogenesis. To the best of our knowledge, this is the first demonstration that NO synthases are not crucial for lymphangiogenesis. Perivascular cells may be important for such a specific requirement of NO in angiogenesis as blood vascular, but not small lymphatic vessels, have a pericyte coverage. 37 We found an interesting correlation between mean capillary size and plasma protein extravasation. VEGFR-2 ligands induce plasma protein extravasation probably by multiple mechanisms. For example, they increase EC surface area, capillary blood flow and pressure, and also have direct effects on EC ultrastructure and vesicle transportation. 38 As shown in this study, cell proliferation is involved in capillary enlargement. Thus, in addition to hemodynamic changes in enlarged microvessels, an increased number of intercellular clefts between dividing ECs, and possibly decreased integrity of the basement membrane may be of importance in vessel leakiness occurring 5 to 6 days after AdVEGF GT. In contrast to this kind of vascular permeability related to angiogenesis, ultrastructural changes and vesicle transport in ECs may be more important in acute plasma protein leakage induced by VEGFs. 4 Ang-1 has been reported to improve the EC barrier function to plasma proteins. 39 However, our data suggest that edema after VEGF GT could be reduced by hindering the excess enlargement of developing vessels. On the other hand, this may not be possible without the restriction of EC and SMC proliferation, which would likely compromise the success of therapeutic angiogenesis. Furthermore, as discussed above, increased plasma protein extravasation may be essential for efficient angiogenesis 35 and arteriogenesis.
Our findings have several important implications. Firstly, they show that at least in nonischemic skeletal muscle the angiogenic effects of VEGF family members comprise microvessel enlargement, pericyte recruitment, and increases in vascular permeability, and not necessarily increases in capillary density. This relationship between angiogenesis and vascular permeability could be used for the judgment of successful gene transfer and for the evaluation of edema after clinical VEGF gene therapy with noninvasive imaging methods such as MRI or ultrasound. Secondly, unlike angiogenesis, lymphangiogenesis is not dependent on VEGFR-2 and NO. Most importantly, this unique comparison of the biological effects generated by different human VEGF family members in vivo provides a classification of human VEGFs as blood or lymphatic vessel growth factors depending on their receptor specificity. The VEGFR-1 ligand VEGF-B is not able to trigger either angiogenesis or lymphangiogenesis in rabbit skeletal muscle, whereas VEGFR-2 and VEGFR-3 ligands are strongly angiogenic and lymphangiogenic, respectively. In conclusion, VEGF-A, VEGF-C, VEGF-C 156S , VEGF-D, and VEGF-D ⌬N⌬C have potential as vascular therapeutics and the most suitable VEGF for each treatment can be chosen based on the need for angiogenesis and/or lymphangiogenesis.
